PMC:7289100 / 42654-42777 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T183","span":{"begin":42,"end":53},"obj":"Chemical"},{"id":"T184","span":{"begin":83,"end":93},"obj":"Chemical"}],"attributes":[{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A184","pred":"chebi_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Over 20 randomized controlled trials with tocilizumab, or sarilumab as well as JAK-inhibitors as baricitinib, are underway."}

{"project":"LitCovid-sentences","denotations":[{"id":"T261","span":{"begin":0,"end":123},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Over 20 randomized controlled trials with tocilizumab, or sarilumab as well as JAK-inhibitors as baricitinib, are underway."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T579","span":{"begin":42,"end":53},"obj":"DG_35"},{"id":"T580","span":{"begin":58,"end":67},"obj":"DG_39"},{"id":"T581","span":{"begin":83,"end":93},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T582","span":{"begin":97,"end":108},"obj":"DG_41"},{"id":"T67676","span":{"begin":42,"end":53},"obj":"DG_35"},{"id":"T51113","span":{"begin":58,"end":67},"obj":"DG_39"},{"id":"T28736","span":{"begin":83,"end":93},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T15613","span":{"begin":97,"end":108},"obj":"DG_41"}],"text":"Over 20 randomized controlled trials with tocilizumab, or sarilumab as well as JAK-inhibitors as baricitinib, are underway."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1425","span":{"begin":42,"end":53},"obj":"Chemical"},{"id":"1426","span":{"begin":58,"end":67},"obj":"Chemical"},{"id":"1427","span":{"begin":97,"end":108},"obj":"Chemical"}],"attributes":[{"id":"A1425","pred":"tao:has_database_id","subj":"1425","obj":"MESH:C502936"},{"id":"A1426","pred":"tao:has_database_id","subj":"1426","obj":"MESH:C000592401"},{"id":"A1427","pred":"tao:has_database_id","subj":"1427","obj":"MESH:C000596027"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Over 20 randomized controlled trials with tocilizumab, or sarilumab as well as JAK-inhibitors as baricitinib, are underway."}